Back to Top Skip to main content

DoD Pharmacy & Therapeutics Committee

The Department of Defense Pharmacy & Therapeutics (DoD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DoD beneficiaries in an effective, efficient, and fiscally responsible manner. 

To learn more, please see the Dec 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified 22 Mar 2005).

DoD P&T Committee Meeting Schedule

View DoD P&T Meeting Minutes See Archived Meeting Pages



May 8-9, 2019

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: February 01, 2019
  • Pre-Proposal Teleconference: February 11, 2019 @ 1100 Central 
  • Clinical/Cost Presentation Meeting Window: February - March, 2019
  • UF BPA & UF ADP Quotes Due: March 29, 2019 
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • PROTON PUMP INHIBITORS - ALTERNATIVE DOSAGE FORMS:
    • Aciphex Sprinkle
    • Nexium Packet
    • Prevacid SoluTab
    • Protonix Packets
    • Zegerid Powder
  • PROTON PUMP INHIBITORS - CAPSULES AND TABLETS:
    • Dexilant
    • Zegerid
  • PULMONARY ARTERIAL HYPERTENSION - ENDOTHELIN RECEPTOR AGONIST:
    • Letairis
    • Opsumit
    • Tracleer
  • PULMONARY ARTERIAL HYPERTENSION - PROSTACYCLIN NEBULIZED THERAPY:
    • Tyvaso
    • Ventavis
  • PULMONARY ARTERIAL HYPERTENSION - PROSTACYCLIN ORAL THERAPY:
    • Orenitram ER
    • Uptravi
  • PULMONARY ARTERIAL HYPERTENSION - SOLUBLE GUANYLATE CYCLASE STIMULATOR:
    • Adempas

 

 

February 6-7, 2019

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: November 01, 2018
  • Pre-Proposal Teleconference: November 06, 2018 @ 1100 Central 
  • Clinical/Cost Presentation Meeting Window: November - December, 2018
  • UF BPA & UF ADP Quotes Due: December 21, 2018 
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • INSULINS - RAPID ACTING AGENTS: -- Solicitation Cancelled
    • Admelog
    • Admelog Solostar
    • Afrezza
    • Apidra
    • Apidra Solostar
    • Fiasp
    • Humalog
    • Humalog Junior Kwikpen
    • Humalog Kwikpen U-100
    • Humalog Kwikpen U-200
    • Novolog
    • Novolog Flexpen
  • MIGRAINE AGENTS - CGRP PREVENTATIVE:
    • Aimovig
    • Ajovy
    • Emgality
  • ONCOLOGICAL AGENTS - 2ND-GEN ANTIANDROGENS:
    • Erleada
    • Xtandi
  • ONCOLOGICAL AGENTS - CYP-17 INHIBITORS:
    • Yonsa
    • Zytiga
  • Abilify Mycite
  • Aemcolo
  • Arakoda

  • Bryhali

  • Cequa

  • Daurismo

  • Firdapse

  • Granix vials

  • Inveltys

  • Krintafel

  • Lexette

  • Lorbrena

  • Nocdurna

  • Nuzyra

  • Oxervate

  • Revcovi

  • Ryclora

  • Seysara

  • Sympazan

  • Talzenna

  • Tegsedi

  • Tiglutik

  • Tolsura

  • Udenyca

  • Vitrakvi

  • Xelpros

  • Xofluza

  • Xospata

  • Xyosted

  • Yupelri

 

November 7-8, 2018

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: August 07, 2018
  • Pre-Proposal Teleconference: August 20, 2018 @ 1300 Central 
  • Clinical/Cost Presentation Meeting Window: August - September, 2018
  • UF BPA & UF ADP Quotes Due: September 28, 2018 
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • NEUROLOGICAL AGENTS MISCELLANEOUS  - MOVEMENT DISORDERS: 
    • Austedo
    • Ingrezza
    • Xenazine
  • GASTROINTESTINAL-2 AGENTS - MISCELLANEOUS:
    • Alinia
    • Dificid
    • Lotronex
    • Viberzi
    • Xifaxan
  • GASTROINTESTINAL-2 AGENTS - CIC AND IBS-C:
    • Amitiza
    • Linzess
    • Trulance
  • Butalbital 50mg with APAP 300mg

  • Adapalene 0.1% topical solution

  • Ajovy

  • Altreno

  • Arikayce

  • Copiktra

  • Crotan

  • Delstrigo

  • Emgality

  • Epidiolex

  • Fulphila

  • Galafold

  • Ilumya

  • Jivi

  • Kapspargo Sprinkle

  • Lokelma

  • Minolira

  • Mulpleta

  • Nivestym

  • Okebo

  • Orilissa

  • Orkambi Granule

  • Pifeltro

  • Plenvu

  • Plixda

  • Qbrexza

  • Symtuza

  • Takhzyro

  • Tibsovo

  • Vizimpro

  • Xepi

  • ZTLido


Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

Decision Papers

File Date
Decision Paper on Implementing ESI Commercial Reject List and Prior Authorization for all Compound Medication Prescriptions 5/8/2015

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing... Download a PDF Reader or learn more about PDFs.